Clinical trial · no report yet · Phase 1
ONKORAS-101
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
- NCT06343402 ↗
- Recruiting
- TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 4 |
The trial
ClinicalTrials.gov- Official title
- A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-8520 in Subjects With Advanced KRASG12C Mutant Non-Small Cell Lung Cancer - The ONKORAS-101 Study
- Phase
- Phase 1
- Status
- Recruiting
- Conditions
- Non-small Cell Lung Cancer; Metastatic Non-Small Cell Lung Cancer; NSCLC; KRAS G12C; Metastatic Lung Cancer; Advanced Lung Carcinoma
- Interventions
- BBO-8520; Pembrolizumab; BBO-10203
- Arms
- Cohort 1a - Dose Escalation/Dose Finding Monotherapy · Experimental
- Cohort 1b - Dose Escalation/Dose Finding Combination Therapy · Experimental
- Cohort 2a - Dose Expansion Monotherapy · Experimental
- Cohort 2b - Dose Expansion Combination Therapy · Experimental
- Cohort 1b Safety Lead-In - Dose Expansion Doublet Combination Therapy · Experimental
- Cohort 1b - Dose Expansion Doublet Combination Therapy · Experimental
- Cohort 1b Safety Lead-In - Dose Expansion Triplet Combination Therapy · Experimental
- Cohort 1b - Dose Expansion Triplet Combination Therapy · Experimental
- Enrollment
- 350 (estimated)
- Primary outcomes
- Adverse Events
- Dose-limiting toxicities (DLTs)
- Sponsor
- TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
- Start
- May 22, 2024
- Primary completion
- Apr 2031 (estimated)
- Results posted
- No
- Registry record
- NCT06343402 · updated Sep 3, 2026